{
    "symbol": "ACB",
    "quarter": 4,
    "year": 2022,
    "date": "2022-09-20 21:15:02",
    "content": " And while our Canadian medical cannabis business is steady, our international business saw revenues increased by over 70% this fiscal year with notable progress in Germany, Poland, the UK and Australia. Taken together, our leading Canadian and global medical businesses performed well, generating $36.6 million in sales and adjusted gross margins of 62%, down only slightly from 64% in the prior quarter. Please proceed with your question. Please proceed with your question. I think, as it pertains to Germany, there\u00e2\u0080\u0099s two things going on as you well know and you\u00e2\u0080\u0099ve written a lot about, is both enhancements to the medical business, which we\u00e2\u0080\u0099re very excited about as one of the leaders in medical cannabis in Germany, and secondly, is the legalization of the rec business. Please proceed with your question. And as you go forward with the advent of things such as clinical research, partnership with clinicians, these systems getting bigger, I think you\u00e2\u0080\u0099re going to still see in most markets, big markets like Germany that three or four companies will do the lion\u00e2\u0080\u0099s share of the business for a long time and we expect Aurora to be one of them. Please proceed with your question. Please proceed with your question."
}